Navigation Links
Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today that the Company intends to initiate a Phase 1b clinical trial to demonstrate the efficacy and safety of the improved formulation of its transdermal insulin product, TPM-02/Insulin, containing long-acting insulin. The trial is expected to commence in the second quarter of 2007.

TPM-02/Insulin gel is being developed as a novel "needle-free" way of administering insulin to patients with diabetes. Following the successful completion of a Phase 1a study utilizing short-acting insulin, this trial will assess an optimized formulation of long-acting insulin. Recent advancements in Phosphagenics' patented TPM-02 delivery system have enabled the formulation of long-acting insulin; which is significantly less expensive than short- acting insulin, provides appropriate levels of insulin in humans and is commercially attractive.

"In August of 2006, our Phase 1a study demonstrated that a single application of TPM-02/Insulin gel rapidly delivered insulin across the skin and into the bloodstream without any adverse reactions," said Dr. Esra Ogru, Executive Vice President at Phosphagenics. "Additionally, it significantly lowered blood glucose, insulin and c-peptide levels."

"The Phase 1b study is intended to provide additional supporting data for an Investigational New Drug application to the U.S. Food and Drug Administration," continued Dr. Ogru. "The trial will be conducted by CMAX at the Royal Adelaide Hospital, South Australia, will include up to 45 healthy volunteers and is expected to lead directly into the start of a large multi- site Phase 2 trial that is likely to include up to several hundred patients."

"This is an important step for the development and commercialization of TPM-02/Insulin," said Harry Rosen, President and CEO of Phosphagenics. "This technology has the potential to p
'"/>




Page: 1 2

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:10/17/2014)... CHAPEL HILL, N.C. , Oct. 17, 2014 ... key insights is a critical success factor in ... companies must develop market research organizations that effectively ... their location, specialty or service area. ... groups create value and earn recognition from internal ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US ... a leading online community and information resource for neurologists and ... and Alzheimer disease , with discussions of the ... 1 million Americans have Parkinson disease , more than ... or Lou Gehrig disease. Diagnosis can be difficult ...
(Date:10/17/2014)... 17, 2014 According ... by Technique (Optical Coherence Tomography, Hyperspectral Imaging, ... (Ophthalmology, Neurology, Oncology, Cardiology) - Global Forecasts ... the Optical Imaging market over the forecast ... at $917.1 million in 2014 and is ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4
... Massachusetts General Hospital (MGH) Cancer Center has purchased four radiation ... Infinity and one Elekta Synergy® S. The order, ... enable the facility to offer patients a complete cancer treatment ... systems position MGH to take advantage of ...
... , MOUNTAIN VIEW, Calif., Oct. 2 Alexza Pharmaceuticals, Inc. ... present a corporate overview during the Fourth Annual JMP Securities ... Hotel in New York. This corporate overview will be ... Eastern Time. , To access the live presentation via the ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference 2Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference 3
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, Fancyflyingfox.com, ... special occasion clothes, has announced its latest designs of ... addition, all the new elegant outfits are offered with ... place an order before October 30 can enjoy this ... and great marketing strategies, it has become one of ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... OLIVE, N.J., Jan 12 InSet Technologies, an emerging ... targeted delivery of medication, announced today the closing of ... venture capital firm, led the round and was joined ... In conjunction with the financing, Kurt C. Wheeler of ...
... Dr. Schoenhaus Perform Foot Fat Pad Restoration on The Balancing ... with comfort and look great doing it" is more than ... experienced foot surgeon, she is a leading expert and innovator ... and legs, but as a woman, she understands the emotional ...
... business in Louisville, Business First of Louisville has named DRE a 2008 ... ... Inc., a premier international medical and surgical equipment supplier, has ... the Year. The award caps the most successful three-year period in DRE’s ...
... research tools to address large, unwarranted variations in project management, ... , ... Phoenixville, Pennsylvania (PRWEB) January ... large and unwarranted variations in corporate spending. As an example, ...
... a drug development company focusing on serious Central Nervous ... it held an initial closing of $2.9 million in ... use the funds for the clinical development of MCD-386, ... down disease progression and improving memory and cognition in ...
... Tenn., Jan. 11 HotHead Technologies, Inc., ... through,research-based technology, today announced it is working ... viable heat-sensing helmet insert, which can,detect potential ... News of their joint,development activities was officially ...
Cached Medicine News:Health News:InSet Technologies Completes $25 Million Financing 2Health News:Kay Renz Steps into PR Position for Cosmetic Foot, Leg and Vein Doctor, Jodi Schoenhaus 2Health News:Business First Selects DRE Medical Equipment as a Company of the Year 2Health News:Business First Selects DRE Medical Equipment as a Company of the Year 3Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:New Venture Funding for Alzheimer's Disease Drug Developer 2Health News:HotHead Technologies Working with Schutt Sports to Develop 'Smart' Helmet 2Health News:HotHead Technologies Working with Schutt Sports to Develop 'Smart' Helmet 3
... Processing Video Camera is our new generation ... Image Processing (IP) technology, the IP 4.2 ... Exciting new features, enhanced image quality, and ... exceptional value. All IP 4.2 cameras are ...
... full lineup of high-powered Xenon, Metal ... optimal brightness in a durable, lightweight ... highest quality light guide cables, providing ... lightweight, durable design., Powerful illumination and ...
... Due to its design, this ... varieties of stone therapy in urinary ... primarily as a multipurpose lithotripter with ... and percutaneous nephrolithotomy. ,The basic system ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
Medicine Products: